• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Femasys Inc (NQ: FEMY )

    1.120 -0.030 (-2.61%)
    Streaming Delayed Price Updated: 3:42 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 63,670
    Open 1.110
    Bid (Size) 1.120 (15)
    Ask (Size) 1.130 (6)
    Prev. Close 1.150
    Today's Range 1.110 - 1.180
    52wk Range 0.2479 - 4.750
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
    Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its products 
    From Femasys Inc.
    Via GlobeNewswire
    Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities

    Performance

    YTD
    +10.89%
    +10.89%
    1 Month
    +10.89%
    +10.89%
    3 Month
    -13.85%
    -13.85%
    6 Month
    +23.92%
    +23.92%
    1 Year
    +180.00%
    +180.00%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Gold Rises 1%; Accenture Shares Surge After Q3 Results
    Via Benzinga
    Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings)
    Via Benzinga
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
    From Femasys Inc.
    Via GlobeNewswire
    EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says
    Via Benzinga
    Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
    From Femasys Inc.
    Via GlobeNewswire
    Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
    From Femasys Inc.
    Via GlobeNewswire
    FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
    From Femasys Inc.
    Via GlobeNewswire
    Femasys Expands Commercial Management Team with Addition of Experienced New Hires
    From Femasys Inc.
    Via GlobeNewswire
    Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
    From Femasys Inc.
    Via GlobeNewswire
    FEMY Stock Earnings: Femasys Beats EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
    From Femasys Inc.
    Via GlobeNewswire
    Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
    From Femasys Inc.
    Via GlobeNewswire
    Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
    From Femasys Inc.
    Via GlobeNewswire
    Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
    From Femasys Inc.
    Via GlobeNewswire
    Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
    From Femasys Inc.
    Via GlobeNewswire
    Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
    From Femasys Inc.
    Via GlobeNewswire
    First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.